Celldex Therapeutics (CLDX) Free Cash Flow (2010 - 2026)

Celldex Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$67.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 23.06% year-over-year to -$67.2 million in Q1 2026; TTM through Mar 2026 was -$226.3 million, a 30.52% decrease from a year earlier, with the FY2025 full-year figure at -$213.7 million, down 33.79% from the prior year.
• Free Cash Flow fell to -$67.2 million in Q1 2026 per CLDX's latest filing, from -$65.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$19.2 million in Q3 2023 and bottomed at -$67.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$33.2 million (2024), against an average of -$38.5 million.
• Across the five-year window, Free Cash Flow soared 46.11% in 2023 and sank 191.81% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$22.0 million in 2022, then slumped by 50.93% to -$33.2 million in 2023, then slipped by 0.1% to -$33.2 million in 2024, then plunged by 96.27% to -$65.2 million in 2025, then retreated by 3.09% to -$67.2 million in 2026.
• Per Business Quant, the three latest CLDX Free Cash Flow figures stand at -$67.2 million (Q1 2026), -$65.2 million (Q4 2025), and -$49.1 million (Q3 2025).